Literature DB >> 20093334

Using activated clotting time to estimate intraoperative aprotinin concentration.

Yusuke Iwata1, Toru Okamura, David Zurakowski, Richard A Jonas.   

Abstract

BACKGROUND: The use of aprotinin during cardiopulmonary bypass may be associated with renal dysfunction due to renal excretion of excess drug. We hypothesized that the difference between standard celite activated clotting time (ACT), which is prolonged by aprotinin, and kaolin ACT could provide an estimate of aprotinin blood level.
METHODS: Fresh porcine blood was collected from six donor pigs and heparinized. Blood was stored at 4 degrees Celsius, rewarmed and aprotinin was added: 0, 100, 200, and 400 kallikrein inhibitor units/ml. Specimens were incubated at 37 degrees Celsius. Two pairs of ACT tubes (one celite and one kaolin) were measured at 37 degrees Celsius and 20 degrees Celsius using two Hemochron 401 machines. A generalized estimating equation (GEE) statistical approach was used to estimate actual aprotinin from differences in celite and kaolin ACT. RESULT: There was a significant relationship of the form y = exp(a+bx) between aprotinin concentration and the difference between celite and kaolin ACT at both 37 degrees Celsius (R(2) = 0.858) and 20 degrees Celsius (R(2) = 0.743).
CONCLUSION: The time difference between celite and kaolin ACT may be a simple and inexpensive method for measuring the blood level of aprotinin during cardiopulmonary bypass. This technique may improve patient-specific dosing of aprotinin and reduce the risk of postoperative renal complications.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20093334      PMCID: PMC2852100          DOI: 10.1177/0267659109358471

Source DB:  PubMed          Journal:  Perfusion        ISSN: 0267-6591            Impact factor:   1.972


  10 in total

1.  Aprotinin improves kidney function and decreases tubular cell apoptosis and proapoptotic signaling after renal ischemia-reperfusion.

Authors:  Ajay Kher; Kirstan K Meldrum; Karen L Hile; Meijing Wang; Ben M Tsai; Mark W Turrentine; John W Brown; Daniel R Meldrum
Journal:  J Thorac Cardiovasc Surg       Date:  2005-09       Impact factor: 5.209

2.  The risk associated with aprotinin in cardiac surgery.

Authors:  Dennis T Mangano; Iulia C Tudor; Cynthia Dietzel
Journal:  N Engl J Med       Date:  2006-01-26       Impact factor: 91.245

3.  Effect of celite and kaolin on activated clotting time in the presence of aprotinin: activated clotting time is reduced by binding of aprotinin to kaolin.

Authors:  W Dietrich; M Jochum
Journal:  J Thorac Cardiovasc Surg       Date:  1995-01       Impact factor: 5.209

4.  Effect of aprotinin on need for blood transfusion after repeat open-heart surgery.

Authors:  D Royston; B P Bidstrup; K M Taylor; R N Sapsford
Journal:  Lancet       Date:  1987-12-05       Impact factor: 79.321

Review 5.  Biochemistry and applications of aprotinin, the kallikrein inhibitor from bovine organs.

Authors:  H Fritz; G Wunderer
Journal:  Arzneimittelforschung       Date:  1983

6.  The impact of renal dysfunction on aprotinin pharmacokinetics during cardiopulmonary bypass.

Authors:  C J O'Connor; D V Brown; M Avramov; S Barnes; H N O'Connor; K J Tuman
Journal:  Anesth Analg       Date:  1999-11       Impact factor: 5.108

7.  A study of a weight-adjusted aprotinin dosing schedule during cardiac surgery.

Authors:  Gregory A Nuttall; David N Fass; Lance J Oyen; William C Oliver; Mark H Ereth
Journal:  Anesth Analg       Date:  2002-02       Impact factor: 5.108

8.  Effects of high-dose aprotinin on renal function in aortocoronary bypass grafting.

Authors:  P R Feindt; S Walcher; I Volkmer; H E Keller; U Straub; H Huwer; U T Seyfert; T Petzold; E Gams
Journal:  Ann Thorac Surg       Date:  1995-10       Impact factor: 4.330

9.  Evaluating the safety implications of aprotinin use: the Retrospective Evaluation of Aprotinin in Cardio Thoracic Surgery (REACTS).

Authors:  Craig I Coleman; Vera T Rigali; Jonathan Hammond; Jeffrey Kluger; Kenneth W Jeleniowski; C Michael White
Journal:  J Thorac Cardiovasc Surg       Date:  2007-06       Impact factor: 5.209

10.  Observations on the early renal uptake and later tubular metabolism of radiolabelled aprotinin (Trasylol) in man: theoretical and practical considerations.

Authors:  R Rustom; J S Grime; P Maltby; H R Stockdale; M Critchley; J M Bone
Journal:  Clin Sci (Lond)       Date:  1993-02       Impact factor: 6.124

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.